Isolasi Dan Karakterisasi Bakteri Endofit Penghasil Inhibitor α-Glukosidase Dari Tanaman Pare (Momordica Charantia L)

Diabetes merupakan penyakit metabolik yang serius di Indonesia. Jumlah penderita diabetes mengalami peningkatan setiap tahunnya. Inhibitor α-glukosidase merupakan senyawa yang dapat menghambat enzim α-glukosidase sehingga bermanfaat sebagai obat antidiabetes. Tanaman Pare (Momordica charantia) diketahui memiliki kasiat sebagai anti diabetes. Senyawa aktif yang dihasilkan tanaman tersebut dapat berasal dari endofit yang hidup di dalam jaringan tanaman. Eksplorasi bakteri endofit dari tanaman pare merupakan salah satu cara untuk mendapatkan isolat bakteri penghasil inhibitor enzim α-glukosidase. Isolasi bakteri dilakukan dengan menginokulasikan sampel tanaman yang telah disterilisasi permukaan pada media agar. Isolat bakteri yang didapat selanjutnya dimurnikan dan di karakterisasi lebih lanjut baik morfologi maupun aktivitas inhibitor α-glukosidasenya. Pengujian aktivitas inhibitor α-glukosidase menggunakan metode spektrofotometer dengan nitrofenil-α-D-glukopiranosida sebagai substrat. Hasil penelitian diperoleh 5 isolat bakteri endofit penghasil inhibior α-glukosidase. Penghambatan terbesar ditunjukkan oleh isolat bakteri Ad 1 yaitu sebesar 27,4%

How to write an ICS/IUGA conference abstract

Contains fulltext : 88292.pdf (publisher's version ) (Closed access)INTRODUCTION: This article aims to condense the lectures and discussions from workshops on good reporting at IUGA Como 2009 and ICS San Francisco 2009, providing practical advice for the novice researcher summarising their data for the first time. CONCLUSIONS: Drafting an abstract can be a time consuming process. Formal guidance, such as CONSORT and STROBE, exists for the kinds of information that should be included regarding almost all designs of clinical trials. Follow the abstract submission rules closely to avoid outright rejection. Plan to highlight the novelty, scientific merit and clinical impact of the work. Try not to overstate the importance of the findings. Do not forget to publish the work in a peer reviewed journal.1 mei 201

Influence of delivery on plasminogen activator inhibitor activity

Peer Reviewe

Development and application of simple expert systems in obstetrics and gynecology

Peer Reviewe

Female pelvic congenital malformations. Part I: embryology, anatomy and surgical treatment.

This review covers the most important female congenital pelvic malformations. The first part focuses on the embryological development of the urogenital and anorectal apparatus, morphological features, and the diagnostic and surgical approach to abnormalities. Comprehension of the embryological development of the urogenital and anorectal apparatus is essential to understand the morphology of congenital pelvic abnormalities and their surgical treatment. Congenital pelvic malformations are characterized by specific common features; the severity of which often subverts the pelvic morphology completely and makes it difficult to comprehend before surgery. The development of imaging, mainly magnetic resonance imaging and ultrasound, in the investigation of pelvic floor disorders has recently become a fundamental tool for surgeons to achieve better understanding of the anatomy. Forty years ago, the primary aim of clinicians was to save the lives of such patients and to achieve anatomical normality. However, nowadays, functional reconstruction and recovery are essential parts of surgical management. Introduction of minimally invasive surgery has allowed the improvement of cosmetic results that is so important in paediatric or adolescent patients after reconstructive surgery. The option of sharing the complexity of pelvic congenital diseases by entrusting specific competencies to subspecialists (paediatric urologists, urogynaecologists, neurourologists, paediatric endocrinologists and neonatologists) has improved the quality of care for patients. However, at the same time, active interaction between various specialists remains fundamental. The exchange of knowledge and expertise, not only during the diagnostic-therapeutic process but also during follow-up, is crucial to obtain the best anatomical and functional results throughout the life of the patient. (C) 2011 Elsevier Ireland Ltd. All rights reserved

Ultrasound Imaging of the Pelvic Floor: Where Are We Going?

We produced a non systematic review of ultrasound imaging of the pelvic floor in women with urinary incontinence (UI) and/or pelvic organ prolapse (POP). We have searched the PubMed and Embase databases for the following PICO question: women; imaging; urinary incontinence, pelvic organ prolapse, pelvic floor, pelvic floor muscle, pelvic floor muscle training; physical examination, no imaging; diagnosis, prognosis, outcome. The production of a systematic review was deemed impossible based on the type and quality of the published evidence. Clinical research focused on the pathophysiology of the UI and POP looking relation between anatomic abnormalities, childbirth, the risk of UI or POP, the outcome of conservative treatment and reconstructive surgery. Published papers fall into the remits of diagnostic studies but often fail to comply with the recommendations of the STARD initiative. Most published evidence remains the product of a single institution effort and confirmatory studies are rarely found. Imaging studies in patients with UI did not provide evidence of any clinical benefit in the management of patients. In patients with POP, interesting correlations have been identified such as between childbirth, dimension of levator hiatus, avulsion of levator ani and risk of prolapse, but the non clinical benefit of pelvic floor imaging could still not be identified. Research on pelvic floor imaging requires a coordinated, international, multicentre effort to improve internal and external validity of imaging techniques, confirm observations published by single institutions and provide health technology assessment of imaging in the management of UI or POP patients. Neurourol. Urodynam 30:729-734, 2011. (C) 2011 Wiley-Liss, Inc

PLOS ONE / The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer A Retrospective Study

Objective The aim of the present study was to investigate the prognostic role of the duration of adjuvant chemotherapy in patients with epithelial ovarian, fallopian tube and primary peritoneal cancer (EOC). Materials and Methods Within the present study we retrospectively evaluated the data of 165 consecutive patients with EOC treated with primary surgery followed by six completed cycles of platinum-taxan based intravenous adjuvant chemotherapy. Medians of total duration of chemotherapy were compared with clinical-pathological parameters. Patients were stratified into four risk groups according to the delay in days of total duration of chemotherapy, and univariate and multivariable survival analyses were performed. Results The median duration of six completed cycles of chemotherapy comprised 113 days (IQR 107124 days). Uni- and multivariable survival analyses revealed a delay of total duration of chemotherapy of at least 9 days to be associated with progression-free (PFS), cancer-specific (CSS) and overall survival (OS). Hazard ratios (HR), confidence intervals (95% CI) and p-values for PFS, CSS and OS due to delay of chemo-duration were 2.9 (1.65.4; p = 0.001), 2.9 (1.36.2; p = 0.008) and 2.6 (1.35.4; p = 0.008), respectively. Prolonged total chemo-duration was associated with the amount of postoperative residual disease (p = 0.001) and the patients age (p = 0.03). Conclusion The present study suggests a prolonged duration of adjuvant chemotherapy after primary surgery to adversely affect PFS, CSS and OS in patients with EOC. Yet larger studies are required to validate our results.(VLID)486839